Pfenex (NASDAQ:PFNX) Lowered to Hold at BidaskClub

Pfenex (NASDAQ:PFNX) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfenex in a research report on Monday, October 28th.

PFNX stock traded down $0.17 during trading on Wednesday, reaching $11.14. 164,246 shares of the company’s stock were exchanged, compared to its average volume of 360,762. Pfenex has a 1-year low of $3.40 and a 1-year high of $13.95. The company has a fifty day simple moving average of $11.82.

Pfenex (NASDAQ:PFNX) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.09 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.09. The business had revenue of $15.25 million for the quarter, compared to analyst estimates of $14.80 million.

Pfenex Company Profile

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

Read More: What is the definition of arbitrage?

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit